【摘要】 为了探讨术后应用铜绿假单胞菌注射液(PA-MSHA)对非小细胞肺癌患者免疫状态的影响,并评估用药的安全性及患者的耐受性。将非小细胞肺癌患者60例,随机分成PA-MSHA治疗组及对照组,每组各30例。PA-MSHA治疗组在手术结束前胸腔注射PA-MSHA 10 mL,术后第4天起开始PA-MSHA皮下注射,1次/d,连续注射10 d;对照组仅进行常规手术。检测患者手术前,以及术后第3、15天的免疫学指标,包括CD3+T、CD4+T、CD8+T、NK细胞及血清IFN-γ水平。PA-MSHA治疗组术后的CD3、CD4、NK及IFNγ-较术前显著升高(P<0.05),而对照组的各项指标较术前无显著变化,P>0.05;PA-MSHA治疗组术后的NK细胞比例和IFNγ-均显著高于对照组,P<0.05。初步研究结果提示,铜绿假单胞菌注射液能显著改善非小细胞肺癌患者术后的免疫状态,安全性及耐受性良好,长期应用后的抗肿瘤疗效值得期待。更多还原

【Abstract】 The objective of this study was to evaluate the effectiveness of postoperative administration of PA-MSHA vaccine on the immunological status of patients with non-small cell lung cancer(NSCLC),and observe the safety and tolerance of patients.A total of 60 patients with pathologically confirmed NSCLC were 1∶1 randomly divided into the PA-MSHA treatment group(30 cases) and control group(30 cases).The patients in PA-MSHA treatment group,10 mL PA-MSHA was directly injected into thoracic cavity at the end of surgery.After 4 days,1 mL PA-MSHA was injected subcutaneously qd for 10 days.The control group was given conventional surgical treatment.The level of CD3+T,CD4+T,CD8+T,NK,and IFN-γ were measured before surgery,3 and 15 days after surgery respectively.The values of CD3+T,CD4+T,NK and IFN-γ of PA-MSHA treatment group after surgery were significant higher than those before surgery(P<0.05),while the changes in control group was not significant(P>0.05).After surgery,the NK and IFN-γ in PA-MSHA treatment group were higher than those in control group(P<0.05).In conclusion,PA-MSHA can enhance the postoperative immunological status of patients with NSCLC and has satisfied safety and tolerance for patients.The anti-tumor efficacy of PA-MSHA would be worth to expect.更多还原